Skip header and navigation

Refine By

182 records – page 1 of 19.

A 25-year follow-up of a population screened with faecal occult blood test in Finland.

https://arctichealth.org/en/permalink/ahliterature161415
Source
Acta Oncol. 2007;46(8):1103-6
Publication Type
Article
Date
2007
Author
Nea Malila
Matti Hakama
Eero Pukkala
Author Affiliation
Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Liisankatu 21 B, FI-001 70 Helsinki, Finland. nea.malila@cancer.fi
Source
Acta Oncol. 2007;46(8):1103-6
Date
2007
Language
English
Publication Type
Article
Keywords
Cohort Studies
Colorectal Neoplasms - diagnosis - epidemiology - mortality
Feasibility Studies
Female
Finland
Follow-Up Studies
Humans
Incidence
Male
Mass Screening - methods
Occult Blood
Patient compliance
Reagent kits, diagnostic
Sensitivity and specificity
Abstract
The aim of the study was to assess the feasibility of and possible selection to attend in colorectal cancer screening.
During the years 1979-1980, 1 785 men and women (born in 1917-1929) were invited to a pilot screening project for colorectal cancer. The screening method used was a guaiac-based faecal occult blood test repeated once if the initial test was positive.
Compliance was 69% and the test was positive in 19% of those attending. In a record linkage with the Finnish Cancer Registry, 47 colorectal cancer cases and 24 deaths from colorectal cancer were observed by the end of 2004. In all, the particular test method was not regarded specific enough for population screening. There was, however, no difference in cancer incidence between those who complied and those who did not when compared to the general population of same age and gender.
Compliance was found high enough to make screening feasible and there was no self selection of persons with low cancer risk to attend screening.
PubMed ID
17851857 View in PubMed
Less detail

[A certain increase of skin cancer among pilots].

https://arctichealth.org/en/permalink/ahliterature184428
Source
Lakartidningen. 2003 Jun 26;100(26-27):2297-9
Publication Type
Article
Date
Jun-26-2003
Author
Niklas Hammar
Harald Eliasch
Anette Linnersjö
Bo-Göran Dammström
Maritha Johansson
Eero Pukkala
Author Affiliation
Enheten för epidemiologi, Institutet för miljömedicin, Karolinska institutet, Stockholm. niklas.hammar@imm.ki.se
Source
Lakartidningen. 2003 Jun 26;100(26-27):2297-9
Date
Jun-26-2003
Language
Swedish
Publication Type
Article
Keywords
Aerospace Medicine - manpower
Aircraft
Cosmic Radiation - adverse effects
Humans
Incidence
Male
Melanoma - epidemiology - etiology
Neoplasms, Radiation-Induced - epidemiology - etiology
Occupational Exposure - adverse effects
Registries
Risk factors
Scandinavia - epidemiology
Skin Neoplasms - epidemiology - etiology
Notes
Comment In: Lakartidningen. 2003 Jun 26;100(26-27):2278-912872371
PubMed ID
12872376 View in PubMed
Less detail

Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients.

https://arctichealth.org/en/permalink/ahliterature16487
Source
J Natl Cancer Inst. 2006 Feb 1;98(3):215-8
Publication Type
Article
Date
Feb-1-2006
Author
Sara J Schonfeld
Ethel S Gilbert
Graça M Dores
Charles F Lynch
David C Hodgson
Per Hall
Hans Storm
Aage Andersen
Eero Pukkala
Eric Holowaty
Magnus Kaijser
Michael Andersson
Heikki Joensuu
Sophie D Fosså
James M Allan
Lois B Travis
Author Affiliation
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892-7238, USA.
Source
J Natl Cancer Inst. 2006 Feb 1;98(3):215-8
Date
Feb-1-2006
Language
English
Publication Type
Article
Keywords
Adult
Antineoplastic Agents - administration & dosage - adverse effects
Confounding Factors (Epidemiology)
Female
Finland - epidemiology
Hodgkin Disease - drug therapy - therapy
Humans
Incidence
Leukemia, Myelocytic, Acute - chemically induced - epidemiology
Male
Middle Aged
Neoplasms, Second Primary - chemically induced - epidemiology
North America - epidemiology
Ontario - epidemiology
Poisson Distribution
Registries
Research Design
Research Support, N.I.H., Intramural
Risk assessment
SEER Program
Scandinavia - epidemiology
Abstract
Treatments for Hodgkin lymphoma are associated with large relative risks of acute myeloid leukemia (AML), but there are few estimates of the excess absolute risk (EAR), a useful measure of disease burden. One-year Hodgkin lymphoma survivors (N = 35,511) were identified within 14 population-based cancer registries in Nordic countries and North America from January 1, 1970, through December 31, 2001. We used Poisson regression analysis to model the EAR of AML, per 10,000 person-years. A total of 217 Hodgkin lymphoma survivors were diagnosed with AML (10.8 expected; unadjusted EAR = 6.2; 95% confidence interval = 5.4 to 7.1). Excess absolute risk for AML was highest during the first 10 years after Hodgkin lymphoma diagnosis but remained elevated thereafter. In subsequent analyses, adjusted for time since Hodgkin lymphoma diagnosis and presented for the 5-9 year interval, the EAR was statistically significantly (P or = 35 age groups, respectively), which may be associated with modifications in chemotherapy.
PubMed ID
16449681 View in PubMed
Less detail

Age-time risk patterns of solid cancers in 60 901 non-Hodgkin lymphoma survivors from Finland, Norway and Sweden.

https://arctichealth.org/en/permalink/ahliterature102725
Source
Br J Haematol. 2014 Mar;164(5):675-83
Publication Type
Article
Date
Mar-2014
Author
Justo Lorenzo Bermejo
Eero Pukkala
Tom B Johannesen
Jan Sundquist
Kari Hemminki
Source
Br J Haematol. 2014 Mar;164(5):675-83
Date
Mar-2014
Language
English
Publication Type
Article
Keywords
Adult
Age Factors
Aged
Aged, 80 and over
Female
Finland - epidemiology
Follow-Up Studies
Humans
Incidence
Lymphoma, Non-Hodgkin - epidemiology - therapy
Male
Middle Aged
Neoplasms, Second Primary - epidemiology - etiology
Norway - epidemiology
Registries
Risk Assessment - methods
Sweden - epidemiology
Time Factors
Abstract
Survival after non-Hodgkin lymphoma (NHL) has increased thanks to improved treatment but NHL survivors have an increased risk of second neoplasms. The assessment of cancer risk patterns after NHL may help to quantify the late side-effects of therapy. Poisson regression was used to estimate relative risks (RRs) and absolute incidence rates for nine solid tumours based on a nationwide cohort of 60 901 NHL survivors from Finland, Norway and Sweden. Patients were diagnosed between 1980 and 2006 and developed 6815 s neoplasms. NHL patients showed an increased risk of each of the nine investigated cancer sites: prostate and pancreas (both RRs 1·28), breast (1·37), colorectum (1·48), urinary bladder (1·52), stomach and lung (both RRs 1·87), skin (melanoma 2·27) and kidney (2·56). The RRs showed a U-shaped relationship with time after NHL for all nine-second cancer types. NHL diagnosis early in life was a risk factor for the development of second cancers with the exception of melanoma, but a risk excess was even observed in patients diagnosed with NHL at age 80+ years. The present study provides accurate estimates on the adverse late effects of NHL therapy, which should guide the establishment of cancer prevention strategies in NHL survivors.
PubMed ID
24528128 View in PubMed
Less detail

Assessing the effect of treatment duration on the association between anti-diabetic medication and cancer risk.

https://arctichealth.org/en/permalink/ahliterature265055
Source
PLoS One. 2014;9(11):e113162
Publication Type
Article
Date
2014
Author
Anna But
Haining Wang
Satu Männistö
Eero Pukkala
Jari Haukka
Source
PLoS One. 2014;9(11):e113162
Date
2014
Language
English
Publication Type
Article
Keywords
Adult
Aged
Body mass index
Cohort Studies
Cross-Sectional Studies
Diabetes Mellitus, Type 1 - drug therapy
Diabetes Mellitus, Type 2 - drug therapy
Female
Finland - epidemiology
Follow-Up Studies
Health Surveys - methods - statistics & numerical data
Humans
Hypoglycemic agents - therapeutic use
Incidence
Male
Middle Aged
Neoplasms - epidemiology
Registries - statistics & numerical data
Risk Assessment - methods - statistics & numerical data
Risk factors
Smoking
Time Factors
Abstract
Most studies that have evaluated the association between anti-diabetic medication and cancer risk have suffered from methodological drawbacks. To avoid time-related biases, we evaluated the effect of treatment duration on the cancer risk among naive users of anti-diabetic medication as compared to non-users. In addition, we addressed the influence of common risk factors such as smoking and BMI. The study population comprised 23,394 participants of FINRISK surveys. Data on cancer and anti-diabetic medication were linked with the study cohorts. We applied Lexis tabulation to the data and analyzed split records by using Poisson regression. Changes in cancer incidence in relation to treatment duration were examined by modeling the rate ratio (RR). After a median follow-up of 9 years, 53 cancer cases among users of anti-diabetic medication and 1,028 among non-users were diagnosed. No significant difference in cancer risk between users and non-users was observed after adjustment. The RR for all medication regardless of its duration was 1.01 [95% CI 0.75-1.33], and 1.37 [0.94-1.94] for period of 1-4 years. The results were similar for metformin, sulfonylurea, and insulin. This study demonstrates that evaluation of the variation in cancer risk in relation to treatment duration is of particular importance for enhancing the accuracy of conclusions on the link between exposure to anti-diabetic medication and cancer risk.
Notes
Cites: Adv Exp Med Biol. 2012;771:229-3923393682
Cites: Cancer Prev Res (Phila). 2014 Sep;7(9):867-8524985407
Cites: Am J Med. 2013 Sep;126(9 Suppl 1):S10-2023953074
Cites: Endocr Pract. 2013 Jul-Aug;19(4):675-9323978590
Cites: Diabetes Care. 2013 Oct;36(10):3070-523990517
Cites: Diabetes Care. 2013 Dec;36(12):3953-6024170756
Cites: Eur J Cancer Prev. 2014 Mar;23(2):134-4023962874
Cites: Lancet Diabetes Endocrinol. 2013 Oct;1(2):132-924622319
Cites: Int J Epidemiol. 2001 Oct;30 Suppl 1:S35-4011759849
Cites: Diabetes Care. 2003 Jan;26(1):61-912502659
Cites: Diabetes Care. 2004 May;27(5):1047-5315111519
Cites: Am J Med. 1992 Jul 15;93(1A):13S-17S1496998
Cites: Acta Oncol. 1994;33(4):365-98018367
Cites: Diabetologia. 2010 Sep;53(9):1867-7620490448
Cites: Diabet Med. 2011 May;28(5):583-921294766
Cites: Diabetologia. 2011 Sep;54(9):2263-7121748485
Cites: Diabetologia. 2012 Mar;55(3):654-6522127412
Cites: APMIS Suppl. 1997;76:141-69462826
Cites: BMJ. 2005 Sep 24;331(7518):65616179700
Cites: Lancet. 2006 May 27;367(9524):1747-5716731270
Cites: JAMA. 2007 Dec 12;298(22):2654-6418073361
Cites: Lancet. 2009 Jun 27;373(9682):2215-2119515410
Cites: Int J Cancer. 2010 Feb 1;126(3):692-70219645011
Cites: Endocr Pract. 2013 Mar-Apr;19(2):327-3623598536
Cites: Am J Med. 2012 Mar;125(3):302.e1-722340932
Cites: Diabetologia. 2012 Apr;55(4):948-5822120574
Cites: Diabetologia. 2012 Jun;55(6):1607-1822476947
Cites: Diabetologia. 2012 Jun;55(6):1619-3222476948
Cites: Diabetes Care. 2012 Dec;35(12):2665-7323173135
Cites: Eur J Cancer. 2014 Aug;50(12):2119-2524930060
Cites: Int J Epidemiol. 2010 Apr;39(2):504-1819959603
PubMed ID
25419576 View in PubMed
Less detail

Associations between three types of maternal bacterial infection and risk of leukemia in the offspring.

https://arctichealth.org/en/permalink/ahliterature16817
Source
Am J Epidemiol. 2005 Oct 1;162(7):662-7
Publication Type
Article
Date
Oct-1-2005
Author
Matti Lehtinen
Helga M Ogmundsdottir
Aini Bloigu
Timo Hakulinen
Elina Hemminki
Margret Gudnadottir
Anne Kjartansdottir
Jorma Paavonen
Eero Pukkala
Hrafn Tulinius
Tuula Lehtinen
Pentti Koskela
Author Affiliation
National Public Health Institute, Helsinki, Finland. llmale@uta.fi
Source
Am J Epidemiol. 2005 Oct 1;162(7):662-7
Date
Oct-1-2005
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age of Onset
Case-Control Studies
Child
Child, Preschool
Chlamydia Infections - epidemiology
Enzyme-Linked Immunosorbent Assay
Female
Finland - epidemiology
Follow-Up Studies
Helicobacter Infections - epidemiology
Helicobacter pylori
Humans
Iceland - epidemiology
Immunoglobulin G - analysis
Immunoglobulin M - analysis
Infant
Infant, Newborn
Leukemia, Lymphocytic, Acute - epidemiology - microbiology
Logistic Models
Pneumonia, Mycoplasma - epidemiology
Population Surveillance
Pregnancy
Pregnancy Complications, Infectious - epidemiology - microbiology
Pregnancy Trimester, First
Registries
Research Support, Non-U.S. Gov't
Risk factors
Abstract
A case-control study was nested within two maternity cohorts with a total of 7 million years of follow-up for assessment of the role of bacterial infections in childhood leukemia. Offspring of 550,000 mothers in Finland and Iceland were combined to form a joint cohort that was followed for cancer up to age 15 years during 1975-1997 through national cancer registries. For each index mother-case pair, three or four matched control mother-control pairs were identified from population registers. First-trimester serum samples were retrieved from mothers of 341 acute lymphoblastic leukemia cases and 61 other leukemia cases and from 1,212 control mothers. Sera were tested for antibodies to the genus Chlamydia, Helicobacter pylori, and Mycoplasma pneumoniae. Odds ratios and 95% confidence intervals, adjusted for sibship size, were calculated as estimates of relative risk. M. pneumoniae immunoglobulin M appeared to be associated with increased risk (odds ratio (OR) = 1.6), but the association lost statistical significance when the specificity of the immunoglobulin M was considered (OR = 1.5, 95% confidence interval: 0.9, 2.4). In Iceland, H. pylori immunoglobulin G was associated with increased risk of childhood leukemia in offspring (OR = 2.8, 95% confidence interval: 1.1, 6.9). Since H. pylori immunoglobulin G indicates chronic carriage of the microorganism, early colonization of the offspring probably differs between Iceland and Finland, two affluent countries.
PubMed ID
16120707 View in PubMed
Less detail

Basal cell carcinoma of the eyelid in Finland during 1953-97.

https://arctichealth.org/en/permalink/ahliterature175502
Source
Acta Ophthalmol Scand. 2005 Apr;83(2):215-20
Publication Type
Article
Date
Apr-2005
Author
Ville Paavilainen
Juhani Tuominen
Eero Pukkala
K Matti Saari
Author Affiliation
Department of Ophthalmology, University of Turku, Turku, Finland.
Source
Acta Ophthalmol Scand. 2005 Apr;83(2):215-20
Date
Apr-2005
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age Distribution
Aged
Aged, 80 and over
Carcinoma, Basal Cell - epidemiology - pathology
Child
Child, Preschool
Eyelid Neoplasms - epidemiology - pathology
Female
Finland - epidemiology
Humans
Incidence
Male
Middle Aged
Occupations
Registries - statistics & numerical data
Sex Distribution
Skin Neoplasms - epidemiology - pathology
Social Class
Abstract
To study the incidence of basal cell carcinoma (BCC) of the eyelid in Finland.
We studied 6241 cases of BCC of the eyelid reported to the nationwide Finnish Cancer Registry during 1953-97. We determined the age- and sex- specific incidence rates and overall rates adjusted for age to the world standard population, and social class- and occupation-specific standardized incidence ratios, with the total Finnish population as reference.
The incidence rates of BCC of the eyelid varied between 0.7 and 3.0 per 100 000 person-years in men and between 0.5 and 2.8 per 100 000 person-years in women during the study period. The age-adjusted incidence rates of BCC of the eyelid increased during 1953-87 (p
PubMed ID
15799736 View in PubMed
Less detail

Blood pressure, smoking, and the incidence of lung cancer in hypertensive men in North Karelia, Finland.

https://arctichealth.org/en/permalink/ahliterature183927
Source
Am J Epidemiol. 2003 Sep 1;158(5):442-7
Publication Type
Article
Date
Sep-1-2003
Author
Annamarja Lindgren
Eero Pukkala
Aulikki Nissinen
Jaakko Tuomilehto
Author Affiliation
Department of Public Health and General Practice, University of Kuopio, Kuopio, Finland. Lindgren@hytti.uku.fi
Source
Am J Epidemiol. 2003 Sep 1;158(5):442-7
Date
Sep-1-2003
Language
English
Publication Type
Article
Keywords
Blood Pressure - physiology
Cohort Studies
Comorbidity
Diastole - physiology
Finland - epidemiology
Follow-Up Studies
Humans
Hypertension - epidemiology - physiopathology
Incidence
Lung Neoplasms - epidemiology
Male
Middle Aged
Multivariate Analysis
Reference Values
Risk factors
Smoking - epidemiology
Systole - physiology
Abstract
Few studies have suggested that elevated blood pressure might be associated with increased risk of lung cancer and that this association might vary according to smoking status. The aim of this study was to assess the effect of blood pressure and its possible interaction with smoking on lung cancer incidence in hypertensive patients. Lung cancer incidence was determined for 7,908 men enrolled in the hypertension register of the North Karelia Project between 1972 and 1988 by record linkage to the nationwide Finnish Cancer Registry. In a Cox regression model, both systolic and diastolic blood pressures were significant predictors of lung cancer, with a 10% increase in risk per 10-mmHg increment in blood pressure. In smokers, the age-adjusted hazard ratio associated with a 10-mmHg increment in diastolic blood pressure was 1.17 (95% confidence interval: 1.05, 1.29), and in nonsmokers it was 0.98 (95% confidence interval: 0.80, 1.16). For systolic blood pressure, these hazard ratios were 1.11 (95% confidence interval: 1.05, 1.17) for smokers and 1.04 (95% confidence interval: 0.95, 1.14) for nonsmokers. These findings suggest that high blood pressure levels are associated with increased risk of lung cancer in smoking, hypertensive men.
PubMed ID
12936899 View in PubMed
Less detail

Body mass index and cancer incidence: the FINRISK study.

https://arctichealth.org/en/permalink/ahliterature103065
Source
Eur J Epidemiol. 2014 Jul;29(7):477-87
Publication Type
Article
Date
Jul-2014
Author
Xin Song
Eero Pukkala
Tadeusz Dyba
Jaakko Tuomilehto
Vladislav Moltchanov
Satu Männistö
Pekka Jousilahti
Qing Qiao
Author Affiliation
Department of Public Health, Hjelt Institute, University of Helsinki, Mannerheimintie 172, PL41, 00014, Helsinki, Finland, xin.song@helsinki.fi.
Source
Eur J Epidemiol. 2014 Jul;29(7):477-87
Date
Jul-2014
Language
English
Publication Type
Article
Keywords
Adult
Aged
Body mass index
Female
Finland - epidemiology
Follow-Up Studies
Humans
Incidence
Linear Models
Male
Middle Aged
Neoplasms - epidemiology
Obesity - epidemiology
Population Surveillance
Prospective Studies
Risk factors
Sex Factors
Smoking - epidemiology
Socioeconomic Factors
Abstract
The relation between body mass index (BMI) and risk of cancer incidence is controversial. Cancer incidence during 1972-2008 in relation to BMI was investigated in a prospective cohort of 54,725 Finns aged 24-74 years and free of cancer at enrollment. Over a mean follow-up of 20.6 years, 8,429 (15.4%) incident cancers were recorded, 4,208 (49.9%) from men. Both parametric and nonparametric approaches were used to evaluate the shape of the relationship between BMI and incidence of cancer. BMI had a linear positive association with incidence of cancers of the colon, liver, kidney, bladder and all sites combined in men, and of cancers of the stomach, colon, gallbladder and ovary in women, an inverse association with incidence of cancers of the lung in men and the lung and breast in women, a J-shaped association with incidence of all cancers combined in women. High BMI in women was associated with an increased overall cancer risk in never smokers but a reduced risk in smokers. Elevated BMI was associated with an increased risk of incidence of cancers of certain sites.
PubMed ID
24997743 View in PubMed
Less detail

Breast cancer risk in postmenopausal women using estradiol-progestogen therapy.

https://arctichealth.org/en/permalink/ahliterature153528
Source
Obstet Gynecol. 2009 Jan;113(1):65-73
Publication Type
Article
Date
Jan-2009
Author
Heli Lyytinen
Eero Pukkala
Olavi Ylikorkala
Author Affiliation
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland.
Source
Obstet Gynecol. 2009 Jan;113(1):65-73
Date
Jan-2009
Language
English
Publication Type
Article
Keywords
Administration, Cutaneous
Administration, Oral
Aged
Aged, 80 and over
Breast Neoplasms - chemically induced - epidemiology
Carcinoma, Ductal, Breast - chemically induced
Carcinoma, Lobular - chemically induced
Drug Administration Schedule
Estradiol - administration & dosage - adverse effects
Estrogen Replacement Therapy - adverse effects
Female
Finland - epidemiology
Humans
Incidence
Middle Aged
Postmenopause
Progestins - administration & dosage - adverse effects
Risk factors
Abstract
To estimate the risk for breast cancer in Finnish women using postmenopausal estradiol (E2)-progestogen therapy.
All Finnish women over 50 years using E2-progestogen therapy for at least 6 months in 1994-2005 (N=221,551) were identified from the national medical reimbursement register and followed up for breast cancer incidence (n=6,211 cases) through the Finnish Cancer Registry to the end of 2005. The risk for breast cancer in E2-progestogen therapy users was compared with that in the general population.
The standardized incidence ratio for all types of breast cancer was not elevated within the first 3 years of use, but it rose to 1.31 (95% confidence interval 1.20-1.42) for the use from 3-5 years and to 2.07 (1.84-2.30) with 10 or more years of use. Exposure to sequential progestogen for 5 years or more was accompanied with a lower risk elevation (1.78, 1.64-1.90) than exposure to continuous use (2.44, 2.17-2.72). Oral and transdermal use of E2-progestogen therapy was associated with comparable risk elevations for breast cancer. The use of norethisterone acetate was accompanied with a higher risk after 5 years of use (2.03, 1.88-2.18) than that of medroxyprogesterone acetate (1.64, 1.49-1.79). The risk of lobular breast cancer increased sooner than that for ductal cancer and was detectable for E2-progestogen therapy use less than 3 years (1.35, 1.18-1.53). There was no excess risk of breast cancer with distant metastases among E2-progestogen therapy users.
The use of E2-progestogen therapy is associated with an increased risk for breast cancer after 3 years of use. The risk is lower for sequential than for continuous use, but comparable for oral and transdermal use. The risk elevation may not be uniform for all progestogens.
II.
Notes
Comment On: Obstet Gynecol. 2009 Jan;113(1):74-8019104362
PubMed ID
19104361 View in PubMed
Less detail

182 records – page 1 of 19.